Humacyte Inc’s recent filing unveils that its President, CEO and Director Niklason Laura E acquired Company’s shares for reported $7979.0 on Nov 19 ’24. In the deal valued at $4.44 per share,1,797 shares were bought. As a result of this transaction, Niklason Laura E now holds 243,851 shares worth roughly $1.09 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Dougan Brady W bought 1,797 shares, generating $7,979 in total proceeds. Upon buying the shares at $4.44, the Director now owns 243,851 shares.
Before that, Niklason Laura E sold 811,172 shares. Humacyte Inc shares valued at $3,601,604 were divested by the President, CEO and Director at a price of $4.44 per share. As a result of the transaction, Niklason Laura E now holds 2,419,712 shares, worth roughly $10.86 million.
H.C. Wainwright initiated its Humacyte Inc [HUMA] rating to a Buy in a research note published on December 11, 2023; the price target was $6. A number of analysts have revised their coverage, including Piper Sandler’s analysts, who increased its forecast for the stock in mid August from “an Underweight” to “a Neutral”. Cantor Fitzgerald began covering HUMA with “an Overweight” recommendation on June 22, 2023. Piper Sandler revised its rating on May 16, 2022. It rated HUMA as “an Underweight” which previously was an “an Overweight”.
Price Performance Review of HUMA
On Friday, Humacyte Inc [NASDAQ:HUMA] saw its stock jump 2.51% to $4.49. Over the last five days, the stock has lost -7.14%. Humacyte Inc shares have risen nearly 58.10% since the year began. Nevertheless, the stocks have risen 76.08% over the past one year. While a 52-week high of $9.97 was reached on 05/31/24, a 52-week low of $2.43 was recorded on 01/17/24. SMA at 50 days reached $5.31, while 200 days put it at $5.41.
Levels Of Support And Resistance For HUMA Stock
The 24-hour chart illustrates a support level at 4.37, which if violated will result in even more drops to 4.26. On the upside, there is a resistance level at 4.56. A further resistance level may holdings at 4.64. The Relative Strength Index (RSI) on the 14-day chart is 37.79, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.55, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 82.65%. Stochastics %K at 14.12% indicates the stock is a buying.
How much short interest is there in Humacyte Inc?
A steep rise in short interest was recorded in Humacyte Inc stocks on 2024-10-31, growing by 1.22 million shares to a total of 17.25 million shares. Yahoo Finance data shows the prior-month short interest on 2024-09-30 was 16.03 million shares. There was a rise of 7.09%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on October 29, 2021 when Cowen began covering the stock and recommended ‘”an Outperform”‘ rating along with a $17 price target.
